Health ❯ Healthcare ❯ Adverse Events

Drug Safety

Side Effects Semaglutide Gastrointestinal Effects Retatrutide Side Effects Patient Monitoring Clinical Outcomes Clinical Study Results Clinical Trial Adverse Events Combination Therapy Risks

FDA Approves Belzutifan With Pembrolizumab as Adjuvant Therapy for Clear Cell Kidney Cancer

Regulators cited LITESPARK-022 results showing reduced recurrence risk, with specific dosing and safety guidance issued.

Spyre Drug Meets Midstage Target in Ulcerative Colitis, Stock Rallies

PrimeC Shows Safety and Potential Benefit in ALS Phase 2b as FDA Authorizes Phase 3

Lilly Reports Zepbound Plus Taltz Beat Taltz Alone in Psoriatic Arthritis Trial

Takeda’s AI-Assisted Psoriasis Pill Succeeds in Phase 3, Outperforms Otezla

Lilly to Launch Late-Stage Trials of Amylin Obesity Drug After 20% Weight Loss in Mid-Stage Study

Phase 3 Trials Show Greater Weight Loss With 7.2 mg Injection and 25 mg Oral Semaglutide